Generics - Oncology, Roche

Filter

Current filters:

OncologyRoche

Popular Filters

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

US FDA approves first generic Xeloda for colorectal and breast cancers

17-09-2013

The US Food and Drug Administration approved the first generic version of Swiss drug major Roche's (ROG:…

capecitabineGenericsNorth AmericaOncologyRegulationRocheTeva Pharmaceutical IndustriesXeloda

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

Back to top